Secondary Antibodies Industry Research Report 2025

Summary

According to APO Research, the global Secondary Antibodies market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.

North American market for Secondary Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Secondary Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Secondary Antibodies is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global manufacturers of Secondary Antibodies include Abbexa (UK), Abcam (UK), Acris Antibodies (Germany), BD Biosciences (US), Bethyl (US), BioLegend (US), BioLogo (Germany), Bio-Rad (US) and Biorbyt (UK), etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Secondary Antibodies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Secondary Antibodies.

The report will help the Secondary Antibodies manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

The Secondary Antibodies market size, estimations, and forecasts are provided in terms of sales volume (Tons) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Secondary Antibodies market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

Key Companies & Market Share Insights

In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Secondary Antibodies Segment by Company

Abbexa (UK)
Abcam (UK)
Acris Antibodies (Germany)
BD Biosciences (US)
Bethyl (US)
BioLegend (US)
BioLogo (Germany)
Bio-Rad (US)
Biorbyt (UK)
Cell Signaling Technology (US)
Dako (US)
Dianova (Germany)
eBioscience (US)
EMD Millipore (US)
GE Healthcare (US)
Jackson ImmunoResearch Laboratories (US)
Kirkegaard & Perry Laboratories (US)
LI-COR Biosciences (US)
R&D Systems (US)
Rockland Immunochemicals (US)
Santa Cruz Biotechnology (US)
Sigma-Aldrich (US)
Sino Biological (China)
SouthernBiotech (US)
Vector Laboratories (US)
Thermo Fisher Scientific (US)
Secondary Antibodies Segment by Type

Men'
Animals'
Secondary Antibodies Segment by Application

Western Blot
ELISA (Including Many HIV Tests)
Immunostaining
Immunocytochemistry
Immunohistochemistry
Secondary Antibodies Segment by Region

North America

United States
Canada
Mexico
Europe

Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific

China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America

Brazil
Argentina
Chile
Middle East Middle East & Africa
Africa

Egypt
South Africa
Israel
Türkiye
GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Secondary Antibodies market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Secondary Antibodies and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Secondary Antibodies.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Secondary Antibodies manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Secondary Antibodies by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Secondary Antibodies in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Preface
1.1 Scope of Report
1.2 Reasons for Doing This Study
1.3 Research Methodology
1.4 Research Process
1.5 Data Source
1.5.1 Secondary Sources
1.5.2 Primary Sources
2 Market Overview
2.1 Product Definition
2.2 Global Market Growth Prospects
2.2.1 Global Secondary Antibodies Market Size (2020-2031)
2.2.2 Global Secondary Antibodies Sales (2020-2031)
2.2.3 Global Secondary Antibodies Market Average Price (2020-2031)
2.3 Secondary Antibodies by Type
2.3.1 Market Value Comparison by Type (2020 VS 2024 VS 2031) & (US$ Million)
2.3.2 Men'
2.3.3 Animals'
2.4 Secondary Antibodies by Application
2.4.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
2.4.2 Western Blot
2.4.3 ELISA (Including Many HIV Tests)
2.4.4 Immunostaining
2.4.5 Immunocytochemistry
2.4.6 Immunohistochemistry
3 Market Competitive Landscape by Manufacturers
3.1 Global Secondary Antibodies Market Competitive Situation by Manufacturers (2020 Versus 2024)
3.2 Global Secondary Antibodies Sales (Tons) of Manufacturers (2020-2025)
3.3 Global Secondary Antibodies Revenue of Manufacturers (2020-2025)
3.4 Global Secondary Antibodies Average Price by Manufacturers (2020-2025)
3.5 Global Secondary Antibodies Industry Ranking, 2023 VS 2024 VS 2025
3.6 Global Manufacturers of Secondary Antibodies, Manufacturing Sites & Headquarters
3.7 Global Manufacturers of Secondary Antibodies, Product Type & Application
3.8 Global Manufacturers of Secondary Antibodies, Established Date
3.9 Global Secondary Antibodies Market CR5 and HHI
3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
4.1 Abbexa (UK)
4.1.1 Abbexa (UK) Company Information
4.1.2 Abbexa (UK) Business Overview
4.1.3 Abbexa (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.1.4 Abbexa (UK) Secondary Antibodies Product Portfolio
4.1.5 Abbexa (UK) Recent Developments
4.2 Abcam (UK)
4.2.1 Abcam (UK) Company Information
4.2.2 Abcam (UK) Business Overview
4.2.3 Abcam (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.2.4 Abcam (UK) Secondary Antibodies Product Portfolio
4.2.5 Abcam (UK) Recent Developments
4.3 Acris Antibodies (Germany)
4.3.1 Acris Antibodies (Germany) Company Information
4.3.2 Acris Antibodies (Germany) Business Overview
4.3.3 Acris Antibodies (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.3.4 Acris Antibodies (Germany) Secondary Antibodies Product Portfolio
4.3.5 Acris Antibodies (Germany) Recent Developments
4.4 BD Biosciences (US)
4.4.1 BD Biosciences (US) Company Information
4.4.2 BD Biosciences (US) Business Overview
4.4.3 BD Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.4.4 BD Biosciences (US) Secondary Antibodies Product Portfolio
4.4.5 BD Biosciences (US) Recent Developments
4.5 Bethyl (US)
4.5.1 Bethyl (US) Company Information
4.5.2 Bethyl (US) Business Overview
4.5.3 Bethyl (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.5.4 Bethyl (US) Secondary Antibodies Product Portfolio
4.5.5 Bethyl (US) Recent Developments
4.6 BioLegend (US)
4.6.1 BioLegend (US) Company Information
4.6.2 BioLegend (US) Business Overview
4.6.3 BioLegend (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.6.4 BioLegend (US) Secondary Antibodies Product Portfolio
4.6.5 BioLegend (US) Recent Developments
4.7 BioLogo (Germany)
4.7.1 BioLogo (Germany) Company Information
4.7.2 BioLogo (Germany) Business Overview
4.7.3 BioLogo (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.7.4 BioLogo (Germany) Secondary Antibodies Product Portfolio
4.7.5 BioLogo (Germany) Recent Developments
4.8 Bio-Rad (US)
4.8.1 Bio-Rad (US) Company Information
4.8.2 Bio-Rad (US) Business Overview
4.8.3 Bio-Rad (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.8.4 Bio-Rad (US) Secondary Antibodies Product Portfolio
4.8.5 Bio-Rad (US) Recent Developments
4.9 Biorbyt (UK)
4.9.1 Biorbyt (UK) Company Information
4.9.2 Biorbyt (UK) Business Overview
4.9.3 Biorbyt (UK) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.9.4 Biorbyt (UK) Secondary Antibodies Product Portfolio
4.9.5 Biorbyt (UK) Recent Developments
4.10 Cell Signaling Technology (US)
4.10.1 Cell Signaling Technology (US) Company Information
4.10.2 Cell Signaling Technology (US) Business Overview
4.10.3 Cell Signaling Technology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.10.4 Cell Signaling Technology (US) Secondary Antibodies Product Portfolio
4.10.5 Cell Signaling Technology (US) Recent Developments
4.11 Dako (US)
4.11.1 Dako (US) Company Information
4.11.2 Dako (US) Business Overview
4.11.3 Dako (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.11.4 Dako (US) Secondary Antibodies Product Portfolio
4.11.5 Dako (US) Recent Developments
4.12 Dianova (Germany)
4.12.1 Dianova (Germany) Company Information
4.12.2 Dianova (Germany) Business Overview
4.12.3 Dianova (Germany) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.12.4 Dianova (Germany) Secondary Antibodies Product Portfolio
4.12.5 Dianova (Germany) Recent Developments
4.13 eBioscience (US)
4.13.1 eBioscience (US) Company Information
4.13.2 eBioscience (US) Business Overview
4.13.3 eBioscience (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.13.4 eBioscience (US) Secondary Antibodies Product Portfolio
4.13.5 eBioscience (US) Recent Developments
4.14 EMD Millipore (US)
4.14.1 EMD Millipore (US) Company Information
4.14.2 EMD Millipore (US) Business Overview
4.14.3 EMD Millipore (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.14.4 EMD Millipore (US) Secondary Antibodies Product Portfolio
4.14.5 EMD Millipore (US) Recent Developments
4.15 GE Healthcare (US)
4.15.1 GE Healthcare (US) Company Information
4.15.2 GE Healthcare (US) Business Overview
4.15.3 GE Healthcare (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.15.4 GE Healthcare (US) Secondary Antibodies Product Portfolio
4.15.5 GE Healthcare (US) Recent Developments
4.16 Jackson ImmunoResearch Laboratories (US)
4.16.1 Jackson ImmunoResearch Laboratories (US) Company Information
4.16.2 Jackson ImmunoResearch Laboratories (US) Business Overview
4.16.3 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.16.4 Jackson ImmunoResearch Laboratories (US) Secondary Antibodies Product Portfolio
4.16.5 Jackson ImmunoResearch Laboratories (US) Recent Developments
4.17 Kirkegaard & Perry Laboratories (US)
4.17.1 Kirkegaard & Perry Laboratories (US) Company Information
4.17.2 Kirkegaard & Perry Laboratories (US) Business Overview
4.17.3 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.17.4 Kirkegaard & Perry Laboratories (US) Secondary Antibodies Product Portfolio
4.17.5 Kirkegaard & Perry Laboratories (US) Recent Developments
4.18 LI-COR Biosciences (US)
4.18.1 LI-COR Biosciences (US) Company Information
4.18.2 LI-COR Biosciences (US) Business Overview
4.18.3 LI-COR Biosciences (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.18.4 LI-COR Biosciences (US) Secondary Antibodies Product Portfolio
4.18.5 LI-COR Biosciences (US) Recent Developments
4.19 R&D Systems (US)
4.19.1 R&D Systems (US) Company Information
4.19.2 R&D Systems (US) Business Overview
4.19.3 R&D Systems (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.19.4 R&D Systems (US) Secondary Antibodies Product Portfolio
4.19.5 R&D Systems (US) Recent Developments
4.20 Rockland Immunochemicals (US)
4.20.1 Rockland Immunochemicals (US) Company Information
4.20.2 Rockland Immunochemicals (US) Business Overview
4.20.3 Rockland Immunochemicals (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.20.4 Rockland Immunochemicals (US) Secondary Antibodies Product Portfolio
4.20.5 Rockland Immunochemicals (US) Recent Developments
4.21 Santa Cruz Biotechnology (US)
4.21.1 Santa Cruz Biotechnology (US) Company Information
4.21.2 Santa Cruz Biotechnology (US) Business Overview
4.21.3 Santa Cruz Biotechnology (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.21.4 Santa Cruz Biotechnology (US) Secondary Antibodies Product Portfolio
4.21.5 Santa Cruz Biotechnology (US) Recent Developments
4.22 Sigma-Aldrich (US)
4.22.1 Sigma-Aldrich (US) Company Information
4.22.2 Sigma-Aldrich (US) Business Overview
4.22.3 Sigma-Aldrich (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.22.4 Sigma-Aldrich (US) Secondary Antibodies Product Portfolio
4.22.5 Sigma-Aldrich (US) Recent Developments
4.23 Sino Biological (China)
4.23.1 Sino Biological (China) Company Information
4.23.2 Sino Biological (China) Business Overview
4.23.3 Sino Biological (China) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.23.4 Sino Biological (China) Secondary Antibodies Product Portfolio
4.23.5 Sino Biological (China) Recent Developments
4.24 SouthernBiotech (US)
4.24.1 SouthernBiotech (US) Company Information
4.24.2 SouthernBiotech (US) Business Overview
4.24.3 SouthernBiotech (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.24.4 SouthernBiotech (US) Secondary Antibodies Product Portfolio
4.24.5 SouthernBiotech (US) Recent Developments
4.25 Vector Laboratories (US)
4.25.1 Vector Laboratories (US) Company Information
4.25.2 Vector Laboratories (US) Business Overview
4.25.3 Vector Laboratories (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.25.4 Vector Laboratories (US) Secondary Antibodies Product Portfolio
4.25.5 Vector Laboratories (US) Recent Developments
4.26 Thermo Fisher Scientific (US)
4.26.1 Thermo Fisher Scientific (US) Company Information
4.26.2 Thermo Fisher Scientific (US) Business Overview
4.26.3 Thermo Fisher Scientific (US) Secondary Antibodies Sales, Revenue and Gross Margin (2020-2025)
4.26.4 Thermo Fisher Scientific (US) Secondary Antibodies Product Portfolio
4.26.5 Thermo Fisher Scientific (US) Recent Developments
5 Global Secondary Antibodies Market Scenario by Region
5.1 Global Secondary Antibodies Market Size by Region: 2020 VS 2024 VS 2031
5.2 Global Secondary Antibodies Sales by Region: 2020-2031
5.2.1 Global Secondary Antibodies Sales by Region: 2020-2025
5.2.2 Global Secondary Antibodies Sales by Region: 2026-2031
5.3 Global Secondary Antibodies Revenue by Region: 2020-2031
5.3.1 Global Secondary Antibodies Revenue by Region: 2020-2025
5.3.2 Global Secondary Antibodies Revenue by Region: 2026-2031
5.4 North America Secondary Antibodies Market Facts & Figures by Country
5.4.1 North America Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
5.4.2 North America Secondary Antibodies Sales by Country (2020-2031)
5.4.3 North America Secondary Antibodies Revenue by Country (2020-2031)
5.4.4 United States
5.4.5 Canada
5.4.6 Mexico
5.5 Europe Secondary Antibodies Market Facts & Figures by Country
5.5.1 Europe Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
5.5.2 Europe Secondary Antibodies Sales by Country (2020-2031)
5.5.3 Europe Secondary Antibodies Revenue by Country (2020-2031)
5.5.4 Germany
5.5.5 France
5.5.6 U.K.
5.5.7 Italy
5.5.8 Russia
5.5.9 Spain
5.5.10 Netherlands
5.5.11 Switzerland
5.5.12 Sweden
5.5.13 Poland
5.6 Asia Pacific Secondary Antibodies Market Facts & Figures by Country
5.6.1 Asia Pacific Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
5.6.2 Asia Pacific Secondary Antibodies Sales by Country (2020-2031)
5.6.3 Asia Pacific Secondary Antibodies Revenue by Country (2020-2031)
5.6.4 China
5.6.5 Japan
5.6.6 South Korea
5.6.7 India
5.6.8 Australia
5.6.9 Taiwan
5.6.10 Southeast Asia
5.7 South America Secondary Antibodies Market Facts & Figures by Country
5.7.1 South America Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
5.7.2 South America Secondary Antibodies Sales by Country (2020-2031)
5.7.3 South America Secondary Antibodies Revenue by Country (2020-2031)
5.7.4 Brazil
5.7.5 Argentina
5.7.6 Chile
5.8 Middle East and Africa Secondary Antibodies Market Facts & Figures by Country
5.8.1 Middle East and Africa Secondary Antibodies Market Size by Country: 2020 VS 2024 VS 2031
5.8.2 Middle East and Africa Secondary Antibodies Sales by Country (2020-2031)
5.8.3 Middle East and Africa Secondary Antibodies Revenue by Country (2020-2031)
5.8.4 Egypt
5.8.5 South Africa
5.8.6 Israel
5.8.7 Türkiye
5.8.8 GCC Countries
6 Segment by Type
6.1 Global Secondary Antibodies Sales by Type (2020-2031)
6.1.1 Global Secondary Antibodies Sales by Type (2020-2031) & (Tons)
6.1.2 Global Secondary Antibodies Sales Market Share by Type (2020-2031)
6.2 Global Secondary Antibodies Revenue by Type (2020-2031)
6.2.1 Global Secondary Antibodies Sales by Type (2020-2031) & (US$ Million)
6.2.2 Global Secondary Antibodies Revenue Market Share by Type (2020-2031)
6.3 Global Secondary Antibodies Price by Type (2020-2031)
7 Segment by Application
7.1 Global Secondary Antibodies Sales by Application (2020-2031)
7.1.1 Global Secondary Antibodies Sales by Application (2020-2031) & (Tons)
7.1.2 Global Secondary Antibodies Sales Market Share by Application (2020-2031)
7.2 Global Secondary Antibodies Revenue by Application (2020-2031)
7.2.1 Global Secondary Antibodies Sales by Application (2020-2031) & (US$ Million)
7.2.2 Global Secondary Antibodies Revenue Market Share by Application (2020-2031)
7.3 Global Secondary Antibodies Price by Application (2020-2031)
8 Value Chain and Sales Channels Analysis of the Market
8.1 Secondary Antibodies Value Chain Analysis
8.1.1 Secondary Antibodies Key Raw Materials
8.1.2 Raw Materials Key Suppliers
8.1.3 Secondary Antibodies Production Mode & Process
8.2 Secondary Antibodies Sales Channels Analysis
8.2.1 Direct Comparison with Distribution Share
8.2.2 Secondary Antibodies Distributors
8.2.3 Secondary Antibodies Customers
9 Global Secondary Antibodies Analyzing Market Dynamics
9.1 Secondary Antibodies Industry Trends
9.2 Secondary Antibodies Industry Drivers
9.3 Secondary Antibodies Industry Opportunities and Challenges
9.4 Secondary Antibodies Industry Restraints
10 Report Conclusion
11 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings